View On Demand

What’s the seduction of enzyme induction?
(and why you should know more)

This webinar will give an overview of induction covering molecular mechanisms, in vitro assessment and clinical impact.

View on demand

Agenda:

• What is enzyme induction and why is it important?
  • General introduction to enzyme induction including molecular mechanisms etc.
• How do we measure enzyme induction? 
  • Introduction of in vitro methods to assess enzyme induction.
  • Theoretical and practical aspects of the methods.
• How do we assess the impact of enzyme induction of new drug molecules? 
  • General principles estimating the clinical impact of a compound as a victim and perpetrator of an enzyme induction drug-drug interaction.

View on demand

Moderated by: Katherine Fenner - Director ADME/DMPK at Pharmaron

Speakers: 

Barry Jones, Ph.D. - Chief Scientist, Global DMPK at Pharmaron

Dr. Barry Jones is the chief scientist for Pharmaron global DMPK based at Hoddesdon and Rushden in the UK. Prior to this, Barry worked in the pharmaceutical industry firstly at Pfizer Global Research & Development in Sandwich from 1990 to 2011 before joining Astrazeneca in 2011 until 2019.

Throughout his industrial career he has focused on setting strategic direction, identifying new opportunities for research/development programs and adding significant insight/expertise and value to drug discovery and development projects with a focus in the area of in vitro DMPK science and drug-drug interactions. Barry gained his Ph. D. from the University of Surrey following research into cytochrome P450-mediated N-dealkylation 1990. He is a long standing member of the Xenobiotica editorial board and has authored or co-authored more than 80 publications.

Yu Wang - Senior Director, in vitro ADME department at Pharmaron

Dr. Wang joined Pharmaron in 2012 and is the senior director of the in vitro ADME department in Beijing. He worked on CYP induction and cell-based transporter studies in his first 3 years of his career. Since 2015, he has been leading an experienced team that supports drug discovery projects for biotech and big pharma clients across the world. He serves as a study director and scientific leader to oversee various in vitro ADME and in vitro toxicity assays. Yu has also led capability development by establishing a high throughput ADME screening platform and in vitro liver tox screening platform at Pharmaron. Before joining Pharmaron, he obtained his Ph.D. in pharmacology from China Agricultural University, and B.Sc. in biology from Beijing Normal University.

Odette Fahmi, Ph.D. - Founder at DDI Edge Consulting

Dr. Fahmi is currently an independent consultant and founder of DDI Edge Consulting (2016-present). Previously, she was in the pharmaceutical industry for 26 years and she was the head of DDI CoE lab at Pfizer. 

Dr. Fahmi is an internationally renowned expert in the field of drug-drug interactions (DDI) with a specialty in the areas of cytochrome P450 (CYP) induction, inhibition, and prediction of clinical DDI risk. She is a key opinion leader in these areas and actively sought after for her expertise by the pharmaceutical industry as well as by regulatory authorities, as reflected by her influence on the current FDA and EMA DDI guidance documents. This is reflected in her involvement as leader and active contributor of many International Consortium for Innovation & Quality in Pharmaceutical Development (IQ) Working groups [e.g. CYP induction and inhibition modeling (in collaboration with the FDA and EMA), CYP2B6 induction, General CYP induction, IVIVC, Biologics DDI working groups] resulting in numerous publications.   She has more than 50 manuscripts/ posters/ chapter book and several podium presentations at national and international meetings.